Derycz Files 13D/A Amendment for Research Solutions
Ticker: RSSS · Form: SC 13D/A · Filed: Nov 18, 2024 · CIK: 1386301
| Field | Detail |
|---|---|
| Company | Research Solutions, Inc. (RSSS) |
| Form Type | SC 13D/A |
| Filed Date | Nov 18, 2024 |
| Risk Level | medium |
| Pages | 3 |
| Reading Time | 4 min |
| Key Dollar Amounts | $0.001 |
| Sentiment | neutral |
Sentiment: neutral
Topics: ownership-change, sec-filing, amendment
Related Tickers: RSOI
TL;DR
Derycz just updated his stake in Research Solutions (RSOI) - check the 13D/A filing.
AI Summary
Peter Derycz filed Amendment No. 9 to Schedule 13D on November 15, 2024, regarding Research Solutions, Inc. This filing indicates a change in beneficial ownership of the company's common stock. Derycz previously operated under the name Derycz Scientific Inc. before a name change on January 12, 2007.
Why It Matters
This filing signals a potential shift in control or significant stake changes for Research Solutions, Inc., which could impact its stock price and strategic direction.
Risk Assessment
Risk Level: medium — Schedule 13D filings often indicate significant ownership changes or activist investor involvement, which can lead to volatility.
Key Players & Entities
- Peter Derycz (person) — Filing person and owner of common stock
- Research Solutions, Inc. (company) — Subject company
- Derycz Scientific Inc (company) — Former name of the subject company
- November 15, 2024 (date) — Date of event requiring filing
- January 12, 2007 (date) — Date of former company name change
FAQ
What is the specific change in beneficial ownership reported in this Amendment No. 9?
The filing does not specify the exact percentage or number of shares changed in this amendment, only that it is an amendment to a Schedule 13D.
What is the CUSIP number for Research Solutions, Inc. common stock?
The CUSIP number for Research Solutions, Inc. common stock is 761025105.
Who is authorized to receive notices and communications for this filing?
Peter Derycz, located at 2355 Westwood Blvd., Suite 739, Los Angeles, CA 90064, is authorized to receive notices and communications.
When was Research Solutions, Inc. formerly known as Derycz Scientific Inc?
Research Solutions, Inc. was formerly known as Derycz Scientific Inc. until January 12, 2007.
What is the business address of Research Solutions, Inc.?
The business address of Research Solutions, Inc. is 10624 S. EASTERN AVE, SUITE A-614, HENDERSON, NV 89052.
Filing Stats: 900 words · 4 min read · ~3 pages · Grade level 11.5 · Accepted 2024-11-18 07:56:06
Key Financial Figures
- $0.001 — Inc. (Name of Issuer) Common stock, $0.001 par value per share (Title of Class o
Filing Documents
- derycz_13da9.htm (SC 13D/A) — 43KB
- 0001683168-24-008201.txt ( ) — 45KB
Security and Issuer
Item 1. Security and Issuer. This Schedule 13D relates to the common stock, par value $0.001 per share (the “Common Stock”), of Research Solutions, Inc., a Nevada corporation (the “Company”), which has its principal executive offices at 5435 Balboa Boulevard, Suite 202, Encino, California 91316.
Identity and Background
Item 2. Identity and Background. This statement is being filed by Peter Derycz, a citizen of the United States of America (the “Reporting Person”).
Purpose of Transaction
Item 4. Purpose of Transaction. Reference is made to the disclosure set forth under Item 3 of this Schedule 13D, which disclosure is incorporated herein by reference. The shares of Common Stock to which this Schedule 13D relates are held by the Reporting Person as an investment. The Reporting Person disclaims any membership in a group relating to the Company. The Reporting Person is not aware of any plans or proposals which would result in the acquisition by any person of additional securities of the Company or the disposition of securities of the Company; any extraordinary corporate transaction, such as a merger, reorganization or liquidation, involving the Company or any of its subsidiaries; a sale or transfer of a material amount of assets of the Company or any of its subsidiaries; any change in the present board of directors or management of the Company, including any plans or proposals to change the number or term of directors or to fill any existing vacancies on the Company's board of directors; any material change in the present capitalization or dividend policy of the Company; any other material change in the Company's business or corporate structure; any changes in Company's charter, bylaws or instruments corresponding thereto or other actions which may impede the acquisition of control of the Company by any person; causing a class of securities of the Company to be delisted from a national securities exchange or to cease to be authorized to be quoted in an inter-dealer quotation system of a registered national securities association; a class of equity securities of the Company becoming eligible for termination of registration pursuant to section 12(g)(4) of the Act; or any action similar to any of those enumerated above.
Interest in Securities of the Issuer
Item 5. Interest in Securities of the Issuer.
of Schedule 13D is
Item 5 of Schedule 13D is supplemented and amended by the information below. Reference is made to the disclosure set forth under Item 3 of this Schedule 13D/A, which disclosure is incorporated herein by reference. The Reporting Person has the sole power vote or direct the vote of, and to dispose of or direct the disposition of all shares beneficially owned by the Reporting Person.
Contracts, Arrangements,
Item 6. Contracts, Arrangements, Understandings or Relationships with Respect to Securities of the Issuer. Reference is made to the disclosure set forth under Items 3, 4 and 5 of this Schedule 13D, which disclosure is incorporated herein by reference.
Material to be Filed as Exhibits
Item 7. Material to be Filed as Exhibits. None. 3
SIGNATURES
SIGNATURES After reasonable inquiry and to the best of his knowledge and belief, the undersigned certifies that the information set forth in this statement is true, complete and correct. Dated: November 18, 2024 /s/ Peter Derycz PETER DERYCZ 4